** Shares of drug developer NeuroBo Pharmaceuticals rise 3.3% to $3.43 premarket
** Co says its obesity drug was found to be safe and well tolerated and did not result in any serious adverse effects in an early-stage study conducted with 45 obese, otherwise healthy individuals
** The main goal of the study was to assess the safety and tolerability of the drug by monitoring adverse events
** Five subjects receiving the treatment reported adverse events vs 3 subjects in the placebo group - NRBO says
** As of last close, stock down 10.2% YTD
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。